Triple inhaler for chronic obstructive pulmonary disease
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a new combination inhaler (fluticasone, formoterol, and glycopyrronium) for people with COPD. It aims to see if this triple therapy can improve breathing and quality of life compared to current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 40 years old.
- You must have a confirmed diagnosis of chronic obstructive pulmonary disease (COPD), shown by a breathing test.
- You cannot be pregnant or breastfeeding.
- You must not have current asthma (but a past history of asthma is okay as long as you have COPD now).
- You must not have other lung conditions like active tuberculosis, sarcoidosis, pulmonary fibrosis, or pulmonary hypertension.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
This study looks at how often heart problems or stroke happen in people with COPD after they start a specific “triple therapy” inhaler. It may help doctors understand whether these inhalers change cardiovascular (heart) or cerebrovascular (stroke) risk.
This study tests an inhaled medication that may help improve breathing and reduce flare-ups in people with moderate-to-severe COPD. If you qualify, you'll use the study drug through a nebulizer at home and have regular check-ups to see how it works.
This study looks at how well a triple inhaler (BDP/FF/GB) works for people with severe COPD in Brazil. It may help those who have had at least one flare-up in the past year.
This study tests a fixed triple combination inhaler (Trimbow) for people whose asthma is not well controlled with their current treatment. It looks at how well this inhaler works in everyday life over time.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.